Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31198231 | 0.75 | — | — | |
| SCHEMBL31424703 | 0.75 | AOC3 (0.31) | — | |
| SCHEMBL21296368 | 0.72 | — | — | |
| SCHEMBL11255816 | 0.69 | — | — | |
| SCHEMBL28261501 | 0.66 | — | — | |
| SCHEMBL27855351 | 0.66 | TSHR (0.41) | CYP1A2 | |
| SCHEMBL5117544 | 0.64 | — | — | |
| Tert-Butanol SCHEMBL27927166 | 0.63 | TSHR (0.39) | CYP1A2 | |
| SCHEMBL27636169 | 0.63 | TSHR (0.39) | CYP1A2 | |
| SCHEMBL31562292 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078133-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2026-03-19 | — | — | US | disclosed |
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| CN-120091998-A | Substituted bicyclic rings as HSET inhibitors | 默克专利股份公司 | 2025-06-03 | — | — | CN | disclosed |
| WO-2025090658-A2 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20250066348-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2025-02-27 | — | — | US | disclosed |
| CN-119173515-A | Small molecule inhibitors of ubiquitin-specific protease 1 (USP 1) and uses thereof | 英矽智能科技知识产权有限公司 | 2024-12-20 | — | — | CN | disclosed |
| EP-4430049-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023083285-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078133-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | MEN1 1379/4885CYP1A2 4033/4885CYP3A4 4263/4885 |
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | CDK2, CDK20, CDK1 | MEN1 2982/4885CYP1A2 3326/4885CYP3A4 2478/4885 |
| US-20250066348-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | USP1, USP2, USP28 | MEN1 2224/4885CYP1A2 3682/4885CYP3A4 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.